Gyre Therapeutics, Inc.
GYRE
$7.01
-$0.64-8.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.24% | 2.13% | -8.42% | -13.01% | -6.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.24% | 2.13% | -8.42% | -13.01% | -6.78% |
| Cost of Revenue | 39.44% | 22.57% | -0.07% | -15.39% | -16.22% |
| Gross Profit | 9.13% | 1.32% | -8.75% | -12.91% | -6.38% |
| SG&A Expenses | 16.79% | -0.04% | 0.37% | -4.89% | -2.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.39% | 0.61% | 0.18% | -5.11% | -5.00% |
| Operating Income | -29.19% | 15.97% | -50.60% | -49.41% | -15.53% |
| Income Before Tax | -37.82% | 119.62% | 116.40% | 121.73% | 130.17% |
| Income Tax Expenses | -14.36% | -40.53% | -66.27% | -59.20% | -37.52% |
| Earnings from Continuing Operations | -44.80% | 114.12% | 111.06% | 114.66% | 120.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 16.51% | 0.19% | 34.49% | 43.60% | 22.00% |
| Net Income | -58.40% | 107.49% | 104.84% | 108.27% | 113.00% |
| EBIT | -29.19% | 15.97% | -50.60% | -49.41% | -15.53% |
| EBITDA | -21.36% | 21.97% | -42.86% | -44.48% | -12.35% |
| EPS Basic | -60.33% | 105.99% | 104.02% | 106.98% | 111.36% |
| Normalized Basic EPS | -59.69% | 282.33% | 22.86% | 213.61% | 783.44% |
| EPS Diluted | -58.56% | 102.83% | 101.24% | 101.55% | 103.66% |
| Normalized Diluted EPS | -59.03% | 190.79% | 631.91% | 598.00% | 322.16% |
| Average Basic Shares Outstanding | 5.05% | 7.76% | 13.85% | 21.38% | 29.26% |
| Average Diluted Shares Outstanding | 1.63% | 3.84% | 10.39% | 17.96% | 27.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |